welcome to DuchenneXchange- a positively charged Duchenne muscular dystrophy community.
- join today!
- log in
A Phase 3 Trial of Pamrevlumab or Placebo in Combination With Systemic Corticosteroids, in Subjects With Non-ambulatory Duchenne Muscular Dystrophy (DMD)
study id #: NCT04371666
condition: Duchenne Muscular Dystrophy
To evaluate the efficacy and safety of pamrevlumab versus placebo in combination with systemic corticosteroids in subjects with non-ambulatory Duchenne muscular dystrophy (age 12 years and older).
intervention: Pamrevlumab, Placebo
mechanism of action: Fibrosis preventor to support muscle
last updated: July 19, 2020
start date: July 30, 2020
estimated completion: August 2022
phase of development: Phase 3
size / enrollment: 90
This is a global, randomized, double-blind trial of pamrevlumab or placebo in combination with systemic corticosteroids in subjects with non-ambulatory Duchenne muscular dystrophy, aged 12 years and older. Approximately 90 male subjects will be randomized at a 1:1 ratio to Arm A (pamrevlumab + systemic corticosteroid) or Arm B (placebo+ systemic corticosteroid), respectively.
Subjects must be fully informed of the potential benefits of approved products and make an informed decision that they prefer to participate in a clinical trial in which they could be randomized to placebo.
Subjects will be randomized in a 1:1 ratio to one of the two study treatment arms; pamrevlumab or placebo in combination with systemic steroids.
This trial has three study periods:
• Screening period: Up to 4 weeks
• Treatment period: 52 weeks
• Safety Follow-up period/final assessment: 4 weeks (Week 56 (+/-3 days))
In the screening period, subjects will be evaluated per the protocol inclusion/exclusion criteria to determine eligibility for participation in this trial.
During the treatment period, each subject will receive pamrevlumab or placebo at 35 mg/kg every 2 weeks for up to 52 weeks.
Subjects who complete the 52-week study (either arm) may be eligible for rollover into an open-label extension treatment (OLE) with pamrevlumab + systemic corticosteroids.
Subjects who discontinue study treatment for any reason should be encouraged to return to the investigative site to complete final safety and efficacy assessments.
- Functional assessment: Change in the total score of Performance of Upper Limb (PUL) 2.0 version [ Time Frame: Baseline to Week 52 ]
- Pulmonary assessment: Change in percent predicted forced vital capacity (ppFVC) assessed by spirometry. [ Time Frame: baseline to Week 52 ]
- Pulmonary assessment: Change in percent predicted peak expiratory flow (ppPEF) assessed by spirometry [ Time Frame: baseline to Week 52 ]
- Performance assessment: Change in the Grip strength of the hands assessed by Hand Held Myometry (HHM). [ Time Frame: baseline to Week 52 ]
- Cardiac assessment: Change in Left Ventricular Ejection Fraction percentage (LVEF %) assessed by MRI. [ Time Frame: baseline to Week 52 ]
• Eligible Sexes: male
• Male subjects with partners of childbearing potential must use contraception during the conduct of the study, and for 3 months after the last dose of study drug.
• Medical history includes diagnosis of DMD and confirmed Duchenne mutation using a validated genetic test
• Brooke Score for Arms and Shoulders =<5
• Able to undergo MRI test for the upper arm extremities (Biceps Brachii muscle) and cardiac muscle
• Able to perform spirometry
• Reproducible (+/- 5% difference between screening and baseline) percent predicted FVC between 45 and 85, inclusive
• Left ventricular ejection fraction >=50% as determined by cardiac MRI at screening or within 3 months prior to randomization (Day 0)
• Prior diagnosis of cardiomyopathy, subjects must be on a stable regimen dose for cardiomyopathy/ heart failure medications (e.g., angiotensin converting enzyme inhibitors, aldosterone receptors blockers, angiotensin-receptor blockers, and betablockers) for at least 1 month prior to screening
• On a stable dose of systemic corticosteroids for a minimum of 6 months, with no substantial change in dosage for a minimum of 3 months (except for adjustments for changes in body weight) prior to screening. Corticosteroid dosage should be in compliance with the DMD Care Considerations Working Group recommendations (e.g.prednisone or prednisolone 0.75 mg/kg per day or deflazacort 0.9 mg/kg per day) or stable dose. A reasonable expectation is that dosage and dosing regimen would not change significantly for the duration of the study.
• Received pneumococcal vaccine (PPSV23) (or any other pneumococcal polysaccharide vaccine as per national recommendations) and is receiving annual influenza vaccinations
• Adequate renal function: cystatin C =<1.4 mg/L
• Adequate hematology and electrolytes parameters:
a. Platelets >100,000/mcL
b. Hemoglobin >12 g/dL
c. Absolute neutrophil count >1500 /μL
d. Serum calcium (Ca), potassium (K), sodium (Na), magnesium (Mg) and phosphorus (P) levels are within a clinically accepted range
• Adequate hepatic function:
a. No history or evidence of liver disease
b. Gamma glutamyl transferase (GGT) =<3x upper limit of normal (ULN)
c. Total bilirubin =<1.5xULN
• Previous exposure to pamrevlumab
• BMI >=40 kg/m2 or weight >117 kg
• History of allergic or anaphylactic reaction to human, humanized, chimeric or murine monoclonal antibodies
• Exposure to any investigational drug (for DMD or not), in the 30 days prior to screening initiation or use of approved DMD therapies (e.g., eteplirsen, ataluren, golodirsen) within 5 half-lives of screening, whichever is longer, with the exception of the systemic corticosteroids, including deflazacort
• Severe uncontrolled heart failure (NYHA Classes III-IV), including any of the following:
a. Need for intravenous diuretics or inotropic support within 8 weeks prior to screening
b. Hospitalization for a heart failure exacerbation or arrhythmia within 8 weeks prior to screening
• Arrhythmia requiring anti-arrhythmic therapy
• Requires >=16 hours continuous ventilation
• Hospitalization due to respiratory failure within the 8 weeks prior to screening
• Poorly controlled asthma or underlying lung disease such as bronchitis, bronchiectasis,emphysema, recurrent pneumonia that in the opinion of the investigator might impact respiratory function
• The Investigator judges that the subject will be unable to fully participate in the study and complete it for any reason, including inability to comply with study procedures and treatment, or any other relevant medical or psychiatric conditions
Potential Mechanisms for Prolonged Loss of Ambulation with Deflazacort in Duchenne Muscular Dystrophy – Tolera...Objective: To summarize prolonged loss ...
A safety and efficacy study of ATL1102 in patients with Duchenne muscular dystrophyCurrent DMD therapies are aimed at incre...
A Pharmacokinetic Study of Oral Deflazacort in Children and Adolescent Subjects With Duchenne Muscular DystrophyStudy to characterize the single-state a...
Corticosteroids for the treatment of Duchenne muscular dystrophyBackground:Duchenne muscular dystrophy (...
The Effect of Steroid Treatment on Weight in Nonambulatory Males with Duchenne Muscular DystrophyTo describe the long-term effect of ster...
Interventions to prevent and treat corticosteroid-induced osteoporosis and prevent osteoporotic fractures in Duchenn...Background:Corticosteroid treatment is c...
Earlier start of corticosteroids in DMD linked to earlier heart disease onset, study suggestsResearchers say it is important to caref...